Core Viewpoint - The AI healthcare sector is experiencing significant growth and interest in 2026, with the AI healthcare index rising over 11% in just 14 trading days, indicating a clear trend in capital market enthusiasm for this sector [1][2]. Market Performance - As of January 22, 2026, the AI healthcare index increased by over 11%, while the CSI Medical Index and Hang Seng Healthcare Index rose by 7.68% and 10.65%, respectively [1]. - Companies like Di'an Diagnostics and Baolait have seen their stock prices surge over 60%, with others like Weining Health and Chengdu Xian Dao also experiencing gains exceeding 30% [1]. Industry Growth Projections - According to Frost & Sullivan, the AI healthcare market in China is projected to grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, with a compound annual growth rate (CAGR) of 43.1% [1]. Technological Advancements - Major tech companies are actively entering the AI healthcare space, with OpenAI launching a healthcare version of ChatGPT and other firms like Ant Group, Tencent, JD, and ByteDance developing AI healthcare models and applications [5][6]. - AI drug development is identified as the fastest-growing segment within AI healthcare, with companies like Insilico Medicine and WuXi AppTec significantly reducing drug development timelines [6][7]. Commercialization Challenges - Despite the enthusiasm, the commercialization of AI healthcare products is facing challenges, with many companies reporting losses. For instance, 24 out of 47 biomedicine companies forecasted losses or reduced profits for 2025 [10]. - Companies like KingMed Diagnostics and Anbiping are experiencing significant revenue declines, with Anbiping reporting a 28.29% drop in revenue year-on-year [10][11]. Regulatory Developments - Recent government policies are seen as a positive signal for the AI healthcare sector, with initiatives aimed at promoting and standardizing AI applications in healthcare [15][16]. - The National Healthcare Security Administration has clarified pricing for AI-assisted diagnostic services, which is expected to facilitate the integration of AI into routine clinical practice [15][16]. Future Outlook - Industry experts predict that 2026 will be a pivotal year for AI healthcare, with clearer payment structures and stronger financial backing expected to enhance commercialization prospects [16].

Group 1: Market Overview - Global stock markets showed mixed performance, with the Hang Seng Index closing at 26,630, up 0.17% for the day and 3.90% year-to-date [1] - The Shanghai Composite Index rose by 0.14% to 4,123, while the Shenzhen Composite Index increased by 0.69% to 2,714, reflecting a positive trend in the Chinese market [1] - The US markets also experienced gains, with the Dow Jones up 0.63% and the S&P 500 up 0.55%, indicating a favorable environment for equities [1] Group 2: Sector Performance - In the Hong Kong market, the real estate sector led gains with a 1.62% increase, while the financial sector saw a decline of 0.37% [2] - The energy, real estate, and public utilities sectors in Hong Kong outperformed, while materials, healthcare, and information technology sectors lagged [3] - The A-share market saw significant gains in construction materials, defense, and oil & petrochemicals, while beauty care, banking, and pharmaceuticals underperformed [3] Group 3: Company Analysis - 康龙化成 (300759 CH) - 康龙化成 is recognized as a leading integrated CXO service provider in China, offering comprehensive drug development services [4] - The company is expected to benefit from the growing global demand for pharmaceutical R&D outsourcing, with a target price set at 38.08 RMB and a "buy" rating [4][8] - The company has established a one-stop CXO service platform, significantly reducing operational risks and costs for clients, which is crucial in the current biopharmaceutical landscape [4] Group 4: Business Growth and Projections - 康龙化成's laboratory services are projected to see over 15% growth in new orders in 2024, providing a solid foundation for revenue [5] - The small molecule CDMO segment is expected to grow over 35% in new orders in 2024, driven by commercialized projects [5] - The company anticipates revenue growth of 14.2% in 2025, with non-IFRS net profit expected to increase by 12.3% [8]

Market Overview - The Hong Kong stock market showed a high opening followed by a pullback, with the Hang Seng Index up 0.32% at 26,715.73 points, the Hang Seng Tech Index up 0.12% at 5,769.23 points, and the China Enterprises Index up 0.33% at 9,144.17 points, while the Red Chip Index fell 0.48% to 4,203.47 points [1] Company News - Prudential (02378.HK) invested approximately $375 million to increase its stake in PAMB to 70%, focusing on traditional life insurance business in Malaysia [2] - Nanjing Panda Electronics (00553.HK) expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [3] - Delta Electronics (00179.HK) reported a revenue of $2.726 billion for the nine months ending December 31, 2025, a decrease of approximately $4 million compared to the same period last year [3] - AsiaInfo Technologies (01675.HK) anticipates revenue of approximately 6.2 billion to 6.35 billion yuan for 2025, with profits expected between 70 million to 110 million yuan [3] - Minmetals Resources (01208.HK) projects a total copper production of 506,900 tons in 2025, representing a 27% year-on-year increase [4] - Charoen Pokphand International (03839.HK) issued a profit warning, expecting a net profit of approximately $32 million for 2025 [5] - Fosun Pharma (02196.HK) plans to spin off its subsidiary Fosun Antengene for a listing on the Hong Kong Stock Exchange [6] - Hisense Home Appliances (00921.HK) and its subsidiaries subscribed to a trust financial product worth 2.035 billion yuan [7] - Xiaomi Group (01810.HK) repurchased 5.7138 million shares for approximately HKD 201 million at prices ranging from HKD 34.92 to HKD 35.24 [8] - Sunny Optical Technology (02382.HK) repurchased 1.25 million shares for approximately HKD 79.26 million at prices between HKD 62.45 and HKD 63.85 [9] - Kuaishou Technology (01024.HK) repurchased approximately 380,000 shares for about HKD 29.97 million at prices ranging from HKD 78.55 to HKD 79.15 [10] - Jiangsu Ninghu Expressway (00177.HK) saw its controlling shareholder increase holdings by 28.4 million H-shares between January 9 and 21, 2026 [11] - Kanglong Chemical (03759.HK) completed a placement of 58.4408 million shares, raising a net amount of HKD 1.319 billion [12] - Ying Tai Medical (01501.HK) completed a placement of 35.20 million shares, raising approximately HKD 884 million [12] Institutional Insights - Industrial Securities suggests that the Hong Kong stock market may continue to trend upwards, with domestic capital inflows expected to persist [13] - Guolian Minsheng expresses strong optimism regarding the revaluation of AI in China, supported by a solid industrial catalyst timeline [13] - JPMorgan forecasts that the upward trend in A-shares and Hong Kong stocks will continue until the Lunar New Year, with Hong Kong stocks expected to outperform A-shares [13][14]

Group 1 - The core viewpoint of the news highlights the positive performance of the medical and healthcare innovation sector, with the China Medical and Medical Device Innovation Index rising by 0.87% and several key stocks showing significant gains [1] - Over 50 biopharmaceutical companies have disclosed their 2025 performance forecasts, with nearly half (27 companies) expecting positive results, indicating a favorable outlook for the sector [1] - The CXO (Contract Research Organization) industry, particularly leading company WuXi AppTec, is projected to achieve approximately 45.46 billion yuan in revenue for 2025, reflecting a year-on-year growth of about 15.84%, and a net profit increase of approximately 102.65% [1] Group 2 - The National Healthcare Security Administration has introduced new policies to accelerate the promotion and adoption of surgical robots and related surgical consumables, which is expected to benefit the overall innovative medical device market [2] - Investors are advised to focus on two main investment themes: the surgical robot industry and its supply chain, as well as high-value consumables in minimally invasive surgery, orthopedics, gastroenterology, cardiovascular, and neurology [2] - The China Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability and growth potential, with the top ten stocks accounting for 63.75% of the index [2]

Market Overview - The Hong Kong stock market opened higher on January 23, with the Hang Seng Index rising by 0.87% to 26,861.36 points, the Hang Seng Tech Index increasing by 0.96% to 5,817.51 points, and the National Enterprises Index up by 0.96% to 9,201.85 points [1] - Major technology stocks saw significant gains, with Alibaba up by 3.88%, JD Group up by 2.63%, Xiaomi up by 0.74%, NetEase up by 0.77%, Meituan up by 0.31%, Kuaishou up by 1.26%, and Bilibili up by 1.4% [1] - Commercial aerospace stocks opened high, with Yunda Holdings rising over 5%, while new consumption concept stocks mostly increased, with Pop Mart rising over 4% [1] - Gold stocks generally rose, with Chifeng Jilong Gold Mining up over 4% [1] Corporate News - Prudential (02378.HK) invested approximately $375 million to increase its stake in PAMB to 70%, focusing on traditional life insurance business in Malaysia [2] - Nanjing Panda Electronics (00553.HK) expects a net profit of between 10 million to 15 million yuan for 2025, marking a turnaround from losses [3] - Delta Electronics (00179.HK) reported a revenue of $2.726 billion for the nine months ending December 31, 2025, a decrease of approximately $4 million compared to the same period last fiscal year [3] - AsiaInfo Technologies (01675.HK) anticipates revenue of approximately 6.2 billion to 6.35 billion yuan for 2025, with profits expected between 70 million to 110 million yuan [3] - Minmetals Resources (01208.HK) projects a total copper production of 506,900 tons in 2025, representing a year-on-year increase of 27% [4] - Charoen Pokphand International (03839.HK) issued a profit warning, expecting a net profit of approximately $32 million for 2025 [5] - Fosun Pharma (02196.HK) plans to spin off its subsidiary Fosun Antengene and list it on the Hong Kong Stock Exchange [6] - Hisense Home Appliances (00921.HK) and its subsidiaries subscribed to a trust financial product worth 2.035 billion yuan [7] - Xiaomi Group (01810.HK) repurchased 5.7138 million shares for approximately HKD 201 million at prices ranging from HKD 34.92 to HKD 35.24 [8] - Sunny Optical Technology (02382.HK) repurchased 1.25 million shares for approximately HKD 79.26 million at prices between HKD 62.45 and HKD 63.85 [9] - Kuaishou (01024.HK) repurchased approximately 380,000 shares for about HKD 29.97 million at prices ranging from HKD 78.55 to HKD 79.15 [10] - Jiangsu Ninghu Expressway (00177.HK) saw its controlling shareholder increase holdings by 28.4 million H-shares from January 9 to 21, 2026 [11] - Kanglong Chemical (03759.HK) completed a placement of 58.4408 million shares, raising a net amount of HKD 1.319 billion [12] - Ying Tai Medical (01501.HK) completed a placement of 35.20 million shares, raising approximately HKD 884 million [12] Institutional Insights - Industrial Securities suggests that the Hong Kong stock market may continue to trend upwards, noting that the recent tightening of funds is easing, leading to continued inflows from domestic investors [13] - Credit Suisse indicates a recovery in Hong Kong property prices, with some new developments experiencing strong sales, predicting a continued upward trend in property prices, albeit at a moderate pace due to cooling interest rate expectations [13] - CITIC Securities believes that the white liquor industry is at a turning point, suggesting that the current adjustment phase may present a bottoming opportunity for capital market investments as the Spring Festival approaches [13]

Group 1 - The three major indices collectively rose, while the National Securities Biopharmaceutical Index (399441) fell by 0.84%. Among its constituent stocks, Kanglong Chemical rose over 1%, Hualan Biological increased by 0.59%, Tigermed gained 0.52%, and Jianfan Biological was up by 0.5% [1] - The Biopharmaceutical ETF (159859) had a trading volume of 100 million yuan yesterday, ranking first among similar products. According to Wind data, the ETF saw a net subscription of over 130 million shares yesterday [1] - As of January 21, the Biopharmaceutical ETF experienced a net inflow of 23.95 million yuan, marking three consecutive trading days of net inflows, with a cumulative net inflow of 116 million yuan [1] Group 2 - The Biopharmaceutical ETF closely tracks the Biopharmaceutical Index, which is based on A-share listed companies in the biopharmaceutical industry, selecting the top 30 stocks based on market capitalization and liquidity [1] - Nine departments, including the Ministry of Commerce and the National Development and Reform Commission, jointly issued opinions to promote high-quality development in the pharmaceutical retail industry, proposing 18 specific measures [1] - According to Pacific Securities, the biopharmaceutical industry will enter a critical phase of innovation realization and global layout by 2026, supported by the synergy of industry, policy, and capital [2]

智通财经APP获悉，香港联交所最新资料显示，1月22日，康龙化成(03759)股东将股票存入摩根士丹利 香港证券，存仓市值12.83亿港元，占比19.38%。 同日，康龙化成发布公告，已达成所有条件并于2026年1月22日完成配售。配售代理已根据配售协议的 条款及条件，按每股配售股份配售价22.82港元，成功向不少于6名独立承配人配售合共5844.08万股配售 股份。 配售的募集资金净额为13.19亿港元，将按以下方式投入使用：约70%将用于公司的项目建设，以加强 公司实验室服务设施、药物工艺开发及生产设施的能力及产能；约10%将用于偿还银行贷款及其他借 款，以优化公司的资本结构；及约20%将用于补充营运资金及作其他一般公司用途。 ...

同日，康龙化成发布公告，已达成所有条件并于2026年1月22日完成配售。配售代理已根据配售协议的 条款及条件，按每股配售股份配售价22.82港元，成功向不少于6名独立承配人配售合共5844.08万股配售 股份。 配售的募集资金净额为13.19亿港元，将按以下方式投入使用：约70%将用于公司的项目建设，以加强 公司实验室服务设施、药物工艺开发及生产设施的能力及产能；约10%将用于偿还银行贷款及其他借 款，以优化公司的资本结构；及约20%将用于补充营运资金及作其他一般公司用途。 香港联交所最新资料显示，1月22日，康龙化成（300759）(03759)股东将股票存入摩根士丹利香港证 券，存仓市值12.83亿港元，占比19.38%。 ...

● 本报记者 李梦扬 根据同花顺iFinD数据，截至1月22日记者发稿时，按照申万一级行业划分，已有逾50家生物医药企业披 露2025年业绩预告，27家预喜，预喜比例近五成。值得关注的是，多家CXO（医药外包服务，包括 CDMO和CRO）公司业绩表现亮眼。其中，CXO行业龙头药明康德预计2025年实现营业收入约454.56亿 元，同比增长约15.84%；实现归母净利润约191.51亿元，同比增长约102.65%。 业内人士表示，随着全球投融资逐步恢复、国内对创新药行业的持续支持以及新药研发逐步回暖， CXO产业趋势向好。2026年，随着行业结构性改革深化、政策与融资环境持续优化，中国医药产业提 质升级趋势明确，行业将迈向高质量发展新阶段。 27家生物医药公司业绩预喜 在已披露业绩预告的超50家生物医药公司中，27家预喜，其中，18家预增，5家略增，4家扭亏。从归母 净利润金额看，药明康德预计2025年实现归母净利润191.51亿元，位居第一；以岭药业、甘李药业、兴 齐眼药、华邦健康等公司居前，预计归母净利润下限均超5亿元。 剔除扭亏影响，从归母净利润同比变动下限看，上海谊众、康辰药业、特一药业、昭衍新药等多家 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 证券代码：300759 证券简称：康龙化成 公告编号：2026-007 康龙化成（北京）新药技术股份有限公司 关于实际控制人及其一致行动人持股比例被动稀释 权益变动触及 1%的公告 本公司实际控制人及其一致行动人保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 中華人民共和 ...